Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine cardioprotection in diabetic patients undergoing CABG
IRCT20120215009014N202Phase 2Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), coronary arteriosclerosis and Coronary artery bypass graft (CABG) comparing N-acetylcysteine with Placebo (2 arms). Started May 2017; status: completed.
02
Drugs
acetylcysteine
03
Conditions
type 2 diabetes mellitus (T2DM)coronary arteriosclerosisCoronary artery bypass graft (CABG)
Beyond the preview
Go deeper on IRCT20120215009014N202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N202.